Hypoxia Transcriptomic Modifications Induced by Proton Irradiation in U87 Glioblastoma Multiforme Cell Line.
glioblastoma
hypoxia
omic science
proton therapy
transcriptome
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
16 Apr 2021
16 Apr 2021
Historique:
received:
17
03
2021
revised:
08
04
2021
accepted:
12
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
In Glioblastoma Multiforme (GBM), hypoxia is associated with radioresistance and poor prognosis. Since standard GBM treatments are not always effective, new strategies are needed to overcome resistance to therapeutic treatments, including radiotherapy (RT). Our study aims to shed light on the biomarker network involved in a hypoxic (0.2% oxygen) GBM cell line that is radioresistant after proton therapy (PT). For cultivating cells in acute hypoxia, GSI's hypoxic chambers were used. Cells were irradiated in the middle of a spread-out Bragg peak with increasing PT doses to verify the greater radioresistance in hypoxic conditions. Whole-genome cDNA microarray gene expression analyses were performed for samples treated with 2 and 10 Gy to highlight biological processes activated in GBM following PT in the hypoxic condition. We describe cell survival response and significant deregulated pathways responsible for the cell death/survival balance and gene signatures linked to the PT/hypoxia configurations assayed. Highlighting the molecular pathways involved in GBM resistance following hypoxia and ionizing radiation (IR), this work could suggest new molecular targets, allowing the development of targeted drugs to be suggested in association with PT.
Identifiants
pubmed: 33923454
pii: jpm11040308
doi: 10.3390/jpm11040308
pmc: PMC8073933
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : PRIN project titled "PBCT Proton Boron Capture Therapy
ID : Prot. 2017 XKWWK9
Organisme : National Institute for Nuclear Physics (INFN) Commissione Scientifica Nazionale 5 (CSN5)
ID : Call 'MoVe-IT'
Références
Biomed Rep. 2016 Aug;5(2):181-187
pubmed: 27446538
J Inflamm (Lond). 2015 Feb 18;12:14
pubmed: 25705130
Oncotarget. 2015;6(12):9820-33
pubmed: 25888632
Cancers (Basel). 2020 Oct 04;12(10):
pubmed: 33020459
Cancer Res. 2018 Sep 1;78(17):5060-5071
pubmed: 29976574
Anticancer Res. 2018 May;38(5):2707-2715
pubmed: 29715090
Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):257-266
pubmed: 31243106
Oncogene. 2020 Jan;39(5):1125-1139
pubmed: 31605013
Cancers (Basel). 2020 Jun 11;12(6):
pubmed: 32545251
Radiat Oncol. 2011 Dec 15;6:171
pubmed: 22172079
Phys Med. 2019 Feb;58:72-80
pubmed: 30824153
Sci Signal. 2016 May 31;9(430):ra56
pubmed: 27245613
J Exp Clin Cancer Res. 2020 Oct 7;39(1):208
pubmed: 33028364
Clin Breast Cancer. 2016 Apr;16(2):113-22.e1
pubmed: 26774497
Mol Carcinog. 2000 Apr;27(4):252-8
pubmed: 10747288
Anticancer Res. 2014 Jun;34(6):2957-66
pubmed: 24922660
Cells. 2019 Jul 19;8(7):
pubmed: 31331111
J Mol Med (Berl). 2007 Dec;85(12):1301-7
pubmed: 18026916
Oncol Lett. 2016 Oct;12(4):2283-2288
pubmed: 27698790
Expert Rev Anticancer Ther. 2016 Jul;16(7):751-8
pubmed: 27253509
J Biol Chem. 2014 Jun 20;289(25):17689-98
pubmed: 24790104
Oncol Rep. 2017 Feb;37(2):657-670
pubmed: 27959421
Nat Cell Biol. 2018 Jul;20(7):823-835
pubmed: 29915361
Int J Mol Sci. 2020 May 30;21(11):
pubmed: 32486205
J Radiat Res. 2019 Jul 1;60(4):451-465
pubmed: 31135901
Oncogene. 2019 Apr;38(15):2788-2799
pubmed: 30542117
Oncotarget. 2017 Sep 23;8(52):90579-90604
pubmed: 29163854
Neuro Oncol. 2021 Feb 25;23(2):284-294
pubmed: 32750703
Eur J Biochem. 2002 Jan;269(1):337-46
pubmed: 11784328
Int J Mol Sci. 2019 Sep 24;20(19):
pubmed: 31554327
Biosci Rep. 2016 Jun 17;36(3):
pubmed: 27129298
Neoplasma. 2008;55(5):369-74
pubmed: 18665745
Sci Rep. 2015 Nov 24;5:17016
pubmed: 26596243
J Clin Invest. 2018 Feb 1;128(2):625-643
pubmed: 29251629
J Radiat Res. 2013 Jul;54 Suppl 1:i23-30
pubmed: 23824123
J Clin Invest. 2014 Oct;124(10):4489-502
pubmed: 25202981
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
FEBS J. 2013 May;280(10):2399-417
pubmed: 23281850
Biochem Biophys Res Commun. 2018 Sep 26;504(1):46-53
pubmed: 30172378
Cancer Res. 2001 Mar 15;61(6):2429-33
pubmed: 11289110
Adv Radiat Oncol. 2020 Apr 22;5(5):978-983
pubmed: 33083661
J Cancer Res Clin Oncol. 2014 Aug;140(8):1261-70
pubmed: 24770633
Cell Death Dis. 2020 Sep 24;11(9):797
pubmed: 32973135
J Neurol Surg A Cent Eur Neurosurg. 2020 Jan;81(1):64-70
pubmed: 31550738
Mol Cancer Res. 2019 May;17(5):1220-1232
pubmed: 30705246
Int J Hyperthermia. 2018 Dec;34(8):1316-1328
pubmed: 29353516
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Int J Mol Sci. 2020 Sep 01;21(17):
pubmed: 32882850
Oncogene. 2019 Jan;38(1):120-139
pubmed: 30082911
Br J Radiol. 2018 Sep;91(1089):20170934
pubmed: 29888960
Cell Biosci. 2019 Aug 13;9:65
pubmed: 31428311
Cancer Res. 2000 Oct 15;60(20):5879-86
pubmed: 11059786
Pract Radiat Oncol. 2016 Jul-Aug;6(4):217-225
pubmed: 27211230
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Cancer Cell Int. 2017 May 12;17:54
pubmed: 28507454
Aging Cell. 2016 Dec;15(6):1113-1125
pubmed: 27586969
Cell Death Dis. 2016 Dec 1;7(12):e2494
pubmed: 27906173
J Biol Chem. 2011 Jun 17;286(24):21588-600
pubmed: 21527635
Cancers (Basel). 2016 Jan 13;8(1):
pubmed: 26771644
Radiat Oncol. 2020 Jun 8;15(1):145
pubmed: 32513205
BMC Bioinformatics. 2003 Dec 10;4:61
pubmed: 14667255
Oncotarget. 2016 Aug 23;7(34):54883-54896
pubmed: 27448972
Neoplasia. 2013 Nov;15(11):1272-81
pubmed: 24339739
Semin Cell Dev Biol. 2019 Nov;95:98-110
pubmed: 30550812
Cell Death Dis. 2020 Nov 18;11(11):992
pubmed: 33208727
Cancer Sci. 2018 Nov;109(11):3519-3531
pubmed: 30191639